Impact of Concomitant Methotrexate Use and Prior Biologic Disease‐Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial

Objective We evaluate tofacitinib efficacy and safety in patients with juvenile idiopathic arthritis (JIA) stratified by concomitant methotrexate and prior biologic disease‐modifying antirheumatic drug (bDMARD) treatment. Methods In this two part, double‐blind, randomized withdrawal Phase 3 trial (N...

Descrición completa

Detalles Bibliográficos

Principais autores:	Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud‐Mendoza, Alberto Spindler, Yulia Vyzhga, Iris Reyhan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Peter Chiraseveenuprapund, Daniel J Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Kevin D. Roberts, Gosford Sawyerr, Andreas Blum, Andrea Shapiro, Annette Diehl, Abbas Ebrahim, Pascal Klaus, Alberto Martini, Hermine I. Brunner, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-10-01
Series:	ACR Open Rheumatology
Acceso en liña:	https://doi.org/10.1002/acr2.70097
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!